Clinical Trial Detail

NCT ID NCT02313272
Title Phase I Trial of HFSRT With Pembrolizumab and Bevacizumab for Recurrent High Grade Gliomas
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors H. Lee Moffitt Cancer Center and Research Institute
Indications

malignant glioma

Therapies

Bevacizumab + Pembrolizumab

Age Groups: adult

No variant requirements are available.